Program

 

 

Day 1 - Thursday, 19 November 2020

 
 08:00Registration and welcome coffee 
 Session 1: Hematology
Chairs: tbc
 
 08:30

Incorporating novel targeted therapies into combination chemotherapy in acute leukemia (tbc)
Keith Pratz
Perelman School of Medicine
University of Pennsylvania, USA

 
 

09:00

Preclinical to clinical translation in leukemia (tbc)
Sharyn Baker
Ohio State University College of Pharmacy, USA

 
  Abstract-driven presentations 
 09:30

 (#01)

 
 09:45(#02) 
 10:00Discussion & session evaluation 
    
 10:30Coffee Break 
    
 Session 2: Therapy optimization
Chairs: tbc
 
 11:00Cell lines vs. Organoids vs. Xenografts (and Organ on a chip) (tbc)
Marc van de Wetering
The Princess Máxima Center, the Netherlands
 
 11:30Immunotherapy and intestinal microbiota
Laurence Zitvogel
Gustave Roussy Cancer Campus, France
 
  Abstract-driven presentations
 
 12:00

 (#03)

 
 12:15(#04) 
 12:30Discussion & session evaluation 
    
 13:00Lunch 
    
 Session 3: Efficient drug development of novel anticancer treatments
Chairs: tbc
 
 14:00

Regulatory aspects on oncology dose finding strategies in an era of streamlined drug development (tbc)
Julie Bullock
Certara, USA

 
 14:30

Early clinical trials - optimized dosing (tbc)
Jesús García-Foncillas
Hospital Jiménez-Díaz, Spain

 
 15:00

Clinical pharmacology in oncology drug development: Enabling rational dose selection from translational to global drug development
Karthik Venkatakrishnan
                     EMD Serono, USA

 
  Abstract-driven presentations 
 15:30 (#05) 
 15:45 (#06) 
 16:00Discussion & session evaluation 
    
 16:30Poster viewing session 1 & welcome drinks 
    
 18:00Networking dinner (optional) 
    
 

Day 2 - Friday, 20 November 2020

 
 Session 4: Drug combinations and Drug interactions
Chairs: tbc
 
 08:30

Optimizing combination cancer therapy in light of patient variability (tbc)
Peter Sorger
Harvard Medical School, USA

 
 09:00

A novel, model based approach to combination, phase I clinical trial design: The ATRiUM trial
Duncan Jodrell
University of Cambridge, UK

 
  Abstract-driven presentations 
 09:30(#07) 
 09:45 (#08) 
 10:00Discussion & session evaluation 
    
 10:30Poster viewing session 2 & coffee break 
    
 Session 5: Pharmacometrics in Drug Development and Clinical Practice
Chairs: tbc
 
 11:00

Physiology-Based Pharmacokinetic (PBPK) Modeling to Support Early Clinical Development in Oncology
Maud Beneton
Servier, France

 
 11:30

How cancer disease state and drug target can influence exposure, making PK-PD analysis challenging
Matts Kågedal
Genentech, Sweden

 
  Abstract-driven presentations 
 12:00(#09) 
 12:15 (#10)

 
 12:30Discussion & session evaluation 
    
 13:00Lunch 
    
 Session 6: Biomarker for Dose Selection in The 2020's
Chairs: tbc
 
 14:00

Biomarker development in immunotherapy
Joachim Aerts
Erasmus MC Cancer Centre, the Netherlands

 
 14:30

Drug selection based on specific mutations in patients with lung cancer (tbc)
Joop de Langen
VU University Medical Center, the Netherlands

 
  Abstract-driven presentation 
 15:00 (#11) 
 15:15(#12) 
 15:30Discussion & session evaluation 
    
  Closing of the workshop by the conference chairs